Clinical Trials: Studies Seeking Participants
| Evaluation of efficacy and safety of an investigational drug in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease. This Phase II study will evaluate the effectiveness and safety of an investigational drug in reducing moderate to severe dyskinesias in people living with Parkinson’s. This study takes place over a period of 13 weeks. The study is looking for men and women between the ages of 30 to 80 years with a confirmed diagnosis of Parkinson’s. Participants should also be receiving treatment for their Parkinson’s symptoms with L-dopa, experiencing dyskinesias for at least three months. The study is not open to anyone who has received surgical treatment for Parkinson’s; has had cancer within the past 5 years; or has an advanced, unstable disease (other than Parkinson’s). More information Investigational medication in early Idiopathic Parkinson’s Disease (IPD), as Add-on to single dopamine agonist (MOTION). The investigational medication is an inhibitor of MAO-B (Monoamine-Oxidase-B). MAO-B compounds enhance the effect of dopamine by preventing its breakdown. The investigational medication is being studied as a phase III trial to evaluate its effectiveness and safety as add-on therapy to a stable dose of a single dopamine agonist. The study will measure the change in motor symptoms, using the Unified Parkinson’s Disease Rating Scale. The study is looking for men and women between the ages of 30 to 80 years with a confirmed diagnosis of Parkinson’s of less than 5 years. Participants should also be receiving treatment for their Parkinson’s symptoms with a single dopamine agonist. Prior to the screening visit, the person should be at a stable dose for at least 4 weeks. More information Investigational medication in Idiopathic Parkinson’s Disease (IPD) With Motor Fluctuations, as Add-on to Levodopa (SETTLE). The investigational medication is an inhibitor of MAO-B (Monoamine-Oxidase-B). MAO-B compounds enhance the effect of dopamine by preventing its breakdown. The investigational medication is being studied as a phase III trial to evaluate its effectiveness and safety as add-on therapy to a stable dose of levodopa. The study will measure the increased daily "on" time for a person with Parkinson’s during an 18-hour diary-recording period. The study is looking for men and women between the ages of 30 to 80 years with a confirmed diagnosis of Parkinson’s of more than 5 years. Participants should also be receiving treatment for their Parkinson’s symptoms with a stable dose of levodopa for at least 4 weeks. More information Ethical Issues in Clinical Trial Participation (December issue of e-ParkinsonPost) |
